Emerging nanomaterials for cfDNA clearance: A new frontier in inflammatory disease therapy
Source abstract
Abstract
Cell-free DNA (cfDNA), a damage-associated molecular pattern, plays a pivotal role in initiating and perpetuating inflammatory responses in a wide range of diseases. Recent advances in nanotechnology have enabled the design of diverse nanomaterials that can bind or degrade cfDNA, offering promising therapeutic avenues. This review systematically summarizes cfDNA-targeting nanomaterials, including cationic polymers, metal-based constructs, and inorganic frameworks for efficient adsorption. Catalytic platforms such as deoxyribonuclease (DNase)-loaded nanocarriers and DNase-mimetic nanozymes are also highlighted for their potential in direct cfDNA degradation. Furthermore, we discuss combinatorial therapeutic strategies that integrate cfDNA clearance with anti-inflammatory therapy, immunomodulation, and reactive oxygen species scavenging to achieve synergistic inflammation control. The therapeutic relevance of these strategies is explored across multiple inflammatory disease models, including autoimmune diseases, infection-induced inflammation, acute injuries, and chronic inflammatory conditions. By bridging nanotechnology and immunopathology, cfDNA-targeted nanomedicine represents a powerful paradigm for precise and durable inflammatory resolution. Finally, we outline current challenges in clinical translation and discuss future directions for the rational design and optimization of cfDNA-scavenging nanotherapeutics.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Advanced nanomedicines for the treatment of inflammatory diseases10.1016/j.addr.2020.07.010 ↗
2. Origin and physiological roles of inflammation10.1038/nature07201 ↗
3. Nonresolving inflammation redux10.1016/j.immuni.2022.03.016 ↗
4. Immune-mediated inflammatory disease therapeutics: past, present and future10.1038/s41577-021-00603-1 ↗
5. Cell-free DNA beyond a biomarker for rejection: biological trigger of tissue injury and potential therapeutics10.1016/j.healun.2021.03.007 ↗
6. The nexus of cfDNA and nuclease biology10.1016/j.tig.2021.04.005 ↗
7. Cell-free DNA and apoptosis: how dead cells inform about the living10.1016/j.molmed.2020.01.012 ↗
8. Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin10.1016/j.cell.2015.11.050 ↗
9. DNA-sensing pathways in health, autoinflammatory and autoimmune diseases10.1038/s41590-024-01966-y ↗
10. cGAS-STING DNA-sensing in inflammatory bowel diseases10.1016/j.molmed.2024.10.002 ↗
11. Capture and storage of cell‐free DNA via bio‐informational hydrogel microspheres10.1002/adma.202403557 ↗
12. Cell-free plasma DNA as a predictor of outcome in severe sepsis and septic shock10.1373/clinchem.2007.101030 ↗
13. Molecular mechanisms and cellular functions of cGAS–STING signalling10.1038/s41580-020-0244-x ↗
14. Ischemic myocardium-derived cell-free DNA activates the type I interferon signaling pathway and mediates reperfusion injury
15. DNA-sensing inflammasomes cause recurrent atherosclerotic stroke10.1038/s41586-024-07803-4 ↗
16. Long-acting nanoparticulate DNase-1 for effective suppression of SARS-CoV-2-mediated neutrophil activities and cytokine storm10.1016/j.biomaterials.2020.120389 ↗
17. Inflammation‐activatable nanoscavengers for sustainable cell‐free DNA capture and cleavage
18. Treatment of lupus nephritis: consensus, evidence and perspectives10.1038/s41584-023-00925-5 ↗
19. A nanoparticulate dual scavenger for targeted therapy of inflammatory bowel disease10.1126/sciadv.abj2372 ↗
20. Tuned cationic dendronized polymer: molecular scavenger for rheumatoid arthritis treatment10.1002/ange.201813362 ↗
21. Prognostic utility and characterization of cell-free DNA in patients with severe sepsis10.1186/cc11466 ↗
22. Pathogenesis activated “In Situ Disassembly‐Reassembly” pattern dual‐scavenges cell‐free DNA/ROS for hemorrhagic stroke management
23. Design of therapeutic biomaterials to control inflammation10.1038/s41578-022-00426-z ↗
24. Scavenging nucleic acid debris to combat autoimmunity and infectious disease10.1073/pnas.1607011113 ↗
25. Treatment of severe sepsis with nanoparticulate cell-free DNA scavengers10.1126/sciadv.aay7148 ↗
26. Nuclease deficiencies alter plasma cell-free DNA methylation profiles10.1101/gr.275426.121 ↗
27. Antibody-modified DNase I micelles specifically recognize the neutrophil extracellular traps (NETs) and promote their degradation10.1016/j.jconrel.2022.12.062 ↗
28. Bioinspired DNase‐I‐coated melanin‐like nanospheres for modulation of infection‐associated NETosis dysregulation
29. Nanotechnology's frontier in combatting infectious and inflammatory diseases: prevention and treatment10.1038/s41392-024-01745-z ↗
30. A biomimetic sweeping microrobot for active therapy of ulcerative colitis
31. Biosilicification-mimicking chiral nanostructures for targeted treatment of inflammatory bowel disease10.1038/s41467-025-57890-8 ↗
32. Nanoparticulate cell-free DNA scavenger for treating inflammatory bone loss in periodontitis10.1038/s41467-022-33492-6 ↗
33. Modulation of unregulated inflammation‐associated coagulopathy in sepsis using multifunctional nanosheets10.1002/adfm.202402785 ↗
34. Polyglycerol‐amine covered nanosheets target cell‐free DNA to attenuate acute kidney injury10.1002/advs.202300604 ↗
35. Functional 2D nanoplatforms alleviate eosinophilic chronic rhinosinusitis by modulating eosinophil extracellular trap formation10.1002/advs.202307800 ↗
36. A cationic metal–organic framework to scavenge cell-free DNA for severe sepsis management10.1021/acs.nanolett.0c04759 ↗
37. DAMPs/PAMPs induce monocytic TLR activation and tolerance in COVID-19 patients; nucleic acid binding scavengers can counteract such TLR agonists10.1016/j.biomaterials.2022.121393 ↗
38. A smart metal-polyphenol-DNAzyme nanoplatform for gene-chemodynamic synergistic tumor therapy10.1016/j.actbio.2023.05.042 ↗
39. Polymeric DNase-I nanozymes targeting neutrophil extracellular traps for the treatment of bowel inflammation10.1186/s40580-024-00414-9 ↗
40. Bioinspired nanogels as cell-free DNA trapping and scavenging organelles for rheumatoid arthritis treatment10.1073/pnas.2303385120 ↗
41. Dexamethasone loaded DNA scavenger nanogel for systemic lupus erythematosus treatment
42. Push-and-Pull nanotherapeutics for osteoarthritis with drug delivery and dual scavenging of reactive oxygen species and cell-free DNA10.1021/acsnano.5c10445 ↗
43. Multifunctional nanoparticle potentiates the in situ vaccination effect of radiation therapy and enhances response to immune checkpoint blockade10.1038/s41467-022-32645-x ↗
44. Targeting lymph nodes for systemic immunosuppression using Cell‐Free‐DNA‐Scavenging and cGAS‐Inhibiting nanomedicine‐in‐hydrogel for rheumatoid arthritis immunotherapy10.1002/advs.202302575 ↗
45. An ROS/DAMP dual-scavenging nanomedicine for normalizing macrophage polarization and microbiome in colitis10.1016/j.nantod.2023.101924 ↗
46. Nucleic acid-binding polymers as anti-inflammatory agents10.1073/pnas.1105777108 ↗
47. 2D is better: engineering polydopamine into cationic nanosheets to enhance anti‐inflammatory capability10.1002/adhm.202400048 ↗
48. A targeted exosome therapeutic confers both CfDNA scavenging and macrophage polarization for ameliorating rheumatoid arthritis10.1002/adma.202302503 ↗
49. Biomimetic encapsulation of mesenchymal stem cells with dendritic polylysine nanogels for lupus nephritis treatment10.1016/j.nantod.2024.102595 ↗
50. Cationic mesoporous silica nanoparticles alleviate osteoarthritis by targeting multiple inflammatory mediators10.1016/j.biomaterials.2023.122366 ↗
51. Cationic block copolymer nanoparticles with tunable DNA affinity for treating rheumatoid arthritis10.1002/adfm.202000391 ↗
52. Nanoparticulate DNA scavenger loading methotrexate targets articular inflammation to enhance rheumatoid arthritis treatment10.1016/j.biomaterials.2022.121594 ↗
53. Therapeutic effects of PEG-modified polyamide amine dendrimer for cell free DNA adsorption in temporomandibular joint osteoarthritis10.1021/acsami.4c08569 ↗
54. Tackling severe neutrophilic inflammation in airway disorders with functionalized nanosheets10.1021/acsnano.3c11139 ↗
55. Inhaled immunoantimicrobials for the treatment of chronic obstructive pulmonary disease10.1126/sciadv.abd7904 ↗
56. Inflammation-responsive polyion complex vesicles for autoimmune disease therapy via cell-free DNA scavenging and inflammatory microenvironment modulation10.1021/acsnano.4c10886 ↗
57. Nanoparticulate cationic poly (amino acid) s block cancer metastases by destructing neutrophil extracellular traps10.1021/acsnano.2c11280 ↗
58. Helix-guarded molecular clips for cell-free DNA scavenging and treatment of systemic lupus erythematosus10.1021/jacs.4c15646 ↗
59. Dimethylamino group modified polydopamine nanoparticles with positive charges to scavenge cell-free DNA for rheumatoid arthritis therapy
60. The protein corona modulates the inflammation inhibition by cationic nanoparticles via cell-free DNA scavenging
61. pH-sensitive cationic nanoparticles for endosomal cell-free DNA scavenging against acute inflammation10.1016/j.jconrel.2024.03.003 ↗
62. Treating acute lung injury through scavenging of cell-free DNA by cationic nanoparticles
63. Targeting multiple mediators of sepsis using multifunctional tannic acid-Zn2+-gentamicin nanoparticles10.1016/j.matt.2021.09.001 ↗
64. A nanoinhibitor targeting cGAS‐STING pathway to reverse the homeostatic imbalance of inflammation in psoriasis10.1002/anie.202316007 ↗
65. Cationic brush hybrid nanoparticles scavenge cell-free DNA to enhance rheumatoid arthritis treatment10.1016/j.actbio.2023.08.032 ↗
66. Topical cationic hairy particles targeting cell free DNA in dermis enhance treatment of psoriasis10.1016/j.biomaterials.2021.121027 ↗
67. Cell-free DNA-scavenging and oxidative stress-interventing Nb2CTx MXene/WS2 nanoflowers for acute kidney injury therapy10.1016/j.memsci.2024.123352 ↗
68. Cationic polymers and their therapeutic potential10.1039/c2cs35094g ↗
69. Polymeric delivery of therapeutic nucleic acids10.1021/acs.chemrev.0c00997 ↗
70. Polydopamine and its derivative surface chemistry in material science: a focused review for studies at KAIST10.1002/adma.201907505 ↗
71. New insights in polydopamine formation via surface adsorption10.1038/s41467-023-36303-8 ↗
72. Intervention of polydopamine assembly and adhesion on nanoscale interfaces: state‐of‐the‐art designs and biomedical applications10.1002/adhm.202002138 ↗
73. Enhancing the sensitivity of polymeric membrane polycation-sensitive electrodes by surface modification of a polydopamine nanolayer10.1016/j.snb.2024.135310 ↗
74. Polydopamine-based simple and versatile surface modification of polymeric nano drug carriers10.1021/nn405809c ↗
75. Polyethylenimine (PEI) in gene therapy: current status and clinical applications10.1016/j.jconrel.2023.09.001 ↗
76. Gold nanoparticles capped with polyethyleneimine for enhanced siRNA delivery10.1002/smll.200901513 ↗
77. Cancer nanomedicine based on polyethylenimine-mediated multifunctional nanosystems10.1016/j.pmatsci.2021.100871 ↗
78. Cytotoxicity of polyethyleneimine (PEI), precursor base layer of polyelectrolyte multilayer films10.1016/j.biomaterials.2006.09.026 ↗
79. Contribution of hydrophobic/hydrophilic modification on cationic chains of poly (ε-caprolactone)-graft-poly (dimethylamino ethylmethacrylate) amphiphilic co-polymer in gene delivery10.1016/j.actbio.2013.09.035 ↗
80. Polymer-mediated inhibition of pro-invasive nucleic acid DAMPs and microvesicles limits pancreatic cancer metastasis10.1016/j.ymthe.2018.02.018 ↗
81. Controlling alveolar bone loss by hydrogel‐based mitigation of oral dysbiosis and bacteria‐triggered proinflammatory immune response10.1002/adfm.202570014 ↗
82. Therapeutic nanocarriers inhibit chemotherapy‐induced breast cancer metastasis10.1002/advs.202203949 ↗
83. PAMAM dendrimer-cell membrane interactions10.1016/j.cis.2018.06.005 ↗
84. Structure-biocompatibility relationship of dendritic polyglycerol derivatives10.1016/j.biomaterials.2010.02.001 ↗
85. Identification of dormancy-associated microRNAs for the design of osteosarcoma-targeted dendritic polyglycerol nanopolyplexes10.1021/acsnano.5b06189 ↗
86. Biodegradable polyamino acid-based polycations as safe and effective gene carrier minimizing cumulative toxicity10.1016/j.biomaterials.2009.11.072 ↗
87. A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer10.1126/sciadv.aaw6071 ↗
88. Fluorinated α-helical polypeptides synchronize mucus permeation and cell penetration toward highly efficient pulmonary siRNA delivery against acute lung injury10.1021/acs.nanolett.9b04957 ↗
89. Antimicrobial polypeptides in host defense of the respiratory tract10.1172/JCI0215218 ↗
90. Recent progress in nucleic acid pulmonary delivery toward overcoming physiological barriers and improving transfection efficiency10.1002/advs.202309748 ↗
91. Synthetic polymers with quaternary nitrogen atoms—Synthesis and structure of the most used type of cationic polyelectrolytes10.1016/j.progpolymsci.2010.01.002 ↗
92. Grafting: a versatile means to modify polymers: techniques, factors and applications10.1016/j.progpolymsci.2004.05.002 ↗
93. Surface functionalisation of polymers10.1039/C7CS00150A ↗
94. Synthesis of functional polymers by post‐polymerization modification10.1002/anie.200801951 ↗
95. Metal‐based nanomaterials in biomedical applications: antimicrobial activity and cytotoxicity aspects10.1002/adfm.201910021 ↗
96. Bioactive material-based nanozymes with multifunctional attributes for biomedicine: expanding antioxidant therapeutics for neuroprotection, cancer, and anti-inflammatory pathologies10.1016/j.ccr.2022.214685 ↗
97. Transition metal‐based therapies for inflammatory diseases10.1002/adma.202212102 ↗
98. From zeolitic Imidazolate Framework‐8 to metal‐organic frameworks (MOF s): representative substance for the general study of pioneering MOF applications10.1002/eem2.12018 ↗
99. Structural evolution of zeolitic imidazolate framework-810.1021/ja109268m ↗
100. Nanoporous crystalline materials for the recognition and applications of nucleic acids